

Neurotech Receives \$10.0 Million in Placement Funds

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces settlement and the receipt of \$10.0 million placement funds (before fees) made to institutional, professional and sophisticated Australian and overseas investors.

MST Financial and Blue Ocean Equities acted as Joint Lead Managers for the Placement.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy

Executive Director

td@neurotechinternational.com

+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has completed recruitment for a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD and a Phase I/II trial in Rett Syndrome and reported Phase I/II clinical trial data in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS. In addition, Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.